ChemoGenix is an academic service platform dedicated to leveraging CRISPR technology to
decode genetic signatures of bioactive compounds. We are part of the Institute for Research in
Immunology and Cancer (IRIC) at the Université de Montréal (UdeM).
Chemical genomics or chemogenomics is a powerful approach to study the response of cells to chemical perturbations. More specifically, genome-wide CRISPR/Cas9 knockout screens in human cells can systematically identify all genes that when deleted either suppress or enhance compound effects on cell proliferation. The resulting chemogenomic signature can directly establish mechanisms-of-action of the compound, uncover off-target effects and reveal new gene functions. Ultimately, this information facilitates the selection of new compounds as promising drug candidates and permits the unveiling of the genetics of cell-drug interactions.
We primarily establish genetic vulnerabilities and resistance to bioactive compounds. We have streamlined the analysis of compounds inhibiting cell proliferation with genome-wide pooled KO screens in the pre-B lymphocytic human cell line NALM6. We are in the process of expanding our screening service to include additional cell models.
We can support any lab interested in screening in different cell lines or with different experimental setups (proliferation, FACS sorting, with or without drugs…).
We can also reveal gene functions through double KO genetic screens querying a single gene of interest KO vs genome-wide KO.
Our services are available to all, including academic institutions and for-profit entities.
The fees charged to academic and non-profit organizations are designed solely to cover the operational expenses of our platform
with the understanding that the data generated will be made publicly accessible three years after the screening results are delivered.
This initiative seeks to establish a comprehensive public repository of chemogenetic data to benefit the biomedical community.
Screens performed for organizations operating on a for-profit basis will be treated with the utmost confidentiality.